Thoracic Surgery (Cardiothoracic Vascular Surgery) Doctors in Downers Grove, IL Accepting Medicare

5 Thoracic Surgery (Cardiothoracic Vascular Surgery) doctors found. Showing 1 - 5

Dr. John G Grieco, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 2650 Warrenville Rd, Suite 280, Downers Grove, IL 60515 Phone: 630-324-7900    Fax: 630-324-7942

Dr. Alyas P Chaudhry, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2650 Warrenville Rd., Ste. 280, Downers Grove, IL 60575 Phone: 630-324-7900    Fax: 630-271-1813

Dr. Marc W Gerdisch, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2650 Warrenville Rd, Suite 280, Downers Grove, IL 60515 Phone: 630-324-7900    Fax: 630-324-7942

Elizabeth Ann Colaiuta, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2650 Warrenville Rd, Ste. 280, Downers Grove, IL 60515 Phone: 630-324-7900

Dr. Bryan K Foy, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2650 Warrenville Rd, Ste 280, Downers Grove, IL 60515 Phone: 630-324-7915    Fax: 630-324-7946

News Archive

Scientists decode new mechanism that regulates cell polarity in epithelial tissues, neurons

In the course of examining the Drosophila tumor suppressor gene (Dlg), scientists at the Helmholtz Zentrum München have succeeded in decoding a new mechanism that regulates cell polarity in epithelial tissues or in neurons in the brain.

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

Alcon board approves merger agreement with Novartis

Alcon, Inc. announced today that its board of directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total merger consideration valued at $168 per share for the Alcon shares it does not currently own. Under the terms of the deal, the merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.

Gut health linked to cardiovascular fitness

It turns out that exercise can do more than slim down your waistline and boost heart health. It might also make what's inside your gut healthier, according to a new study by San Francisco State University.

New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis

A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published today in Science Translational Medicine.

Read more Medical News

› Verified 6 days ago